Initially proposed as an inhibitor of the MAP3K for ERK1/2, Raf, latter on it was shown to block key tyrosine kinase receptors in tumour progression such as platelet‐derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR).1 Here, PDGFRB is linked to neoplasm.